Internal Server Error

About Tech Council Ventures

Tech Council Ventures is a venture capital firm founded in 2000. It is primarily based out of Summit, United States. As of Sep 2026, Tech Council Ventures is an active investor, having invested in 46 companies, with 3 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Enterprise Applications to Life Sciences and HealthTech. Most recently it participated in the $***** Series A round of Diameter Pay Overall, Tech Council Ventures portfolio has seen 1 IPO and 18 acquisitions including key companies like Nuance, IntegriChain and Cytosorbents. A lot of funds co-invest with Tech Council Ventures, with names like Boston Millennia Partners sharing a substantial percentage of its portfolio. Tech Council Ventures has team of 6 people including 4 partners.
Key Metrics
Portfolio Count
Portfolio Locations
Rounds of Entry
Series A, Seed & 1 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months

Tech Council Ventures' List of Top Investments

Tech Council Ventures has a portfolio of 46 companies. Their most notable investments are in CatherineGives and ChoiceWorx.Their portfolio spans across United States, Australia and Israel. They have invested in Enterprise Applications, Life Sciences, HealthTech and 19 other sectors, across stages such as Series A, Seed  and 1 more. Here is the list of top investments by Tech Council Ventures:
Developer of speech recognition software for healthcare and productivity applications. This software converts spoken language into text to assist physicians, radiologists, and office workers with documentation tasks. These applications facilitate information capture and data entry to support professional workflows.

Key facts about Nuance

  • Founded Year: 1992
  • Location: Burlington (United States)
  • Annual Revenue: $1B+ as on Sep 30, 2021
  • Stage: Acquired
  • Total Funding till date: $15.6M
  • Employee Count: 3,301 as on Sep 30, 2026
  • Investors: Intel, Goldman Sachs and 20 Others
  • Latest Funding Round: Post IPO, May 28, 2021, $*****
  • Highlight: Acquired
Pharma commercialization solutions: data, consulting, and technology for market access. The company offers a comprehensive suite of services and a platform designed to address the complexities of drug commercialization. It provides strategy, data, applications, and infrastructure for therapy commercialization, focusing on optimizing price and demand through integrated commercial and net revenue analytics. The company delivers solutions for net revenue management, commercial data, and insights, helping pharmaceutical manufacturers bring their science to market. Its offerings include consulting and advisory services, regulatory compliance, market access strategy, and data and technology solutions. The company empowers pharma companies to build efficient access, affordability, and distribution strategies, maximizing net revenue. It unifies critical business functions like contracts & pricing, gross-to-net, channel, and patient services to unlock strategic insights. The platform supports data visualization, AI enablement, and data management services. It is a B2B company offering SaaS and software solutions.

Key facts about IntegriChain

Developer of hemoperfusion technology for removing toxins from the blood. It develops and manufactures therapeutic devices that purify the blood. Its purification technology is based on biocompatible, porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.

Key facts about Cytosorbents

  • Founded Year: 1997
  • Location: Monmouth Junction (United States)
  • Annual Revenue: $10M - $50M as on Dec 31, 2025
  • Stage: Public
  • Total Funding till date: $22M
  • Employee Count: 140 as on Sep 30, 2026
  • Investors: Western Alliance Bank, NJTC Venture Fund and 5 Others
  • Latest Funding Round: Grant (prize money), Oct 27, 2025, $*****
  • Highlight: Public
Provider of data management solutions. The platform helps in curating medical information from various sources and allows healthcare professionals to securely transfer medical data for their patients. The data analytics platform enables professionals to manage their patient engagement, administrative solutions, and care management.

Key facts about Abacus Insights

Transforming cancer care through real-world data and insights. They empower oncology research, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care. They offer curated databases of oncology patient data, analytics solutions, and expert clinical insights to expedite timelines, support regulatory submissions, validate commercial strategies, and carry out post-marketing studies. Their services help oncology practices and cancer centers make sense of fragmented EHR data. They provide high-quality cancer real-world data and insights, including longitudinal real-world outcomes datasets curated to specific cancer types and subpopulations. They leverage technology-driven curation with deep oncology expertise to provide credible, complete, and clinically meaningful data. They are focused on building datasets with a specific use case in mind, supporting external control arms, uncovering treatment patterns, and informing regulatory-grade evidence.

Key facts about Cota Healthcare

  • Founded Year: 2013
  • Location: New York City (United States)
  • Valuation: $*****
  • Stage: Series D
  • Total Funding till date: $103M
  • Employee Count: 228 as on Aug 31, 2026
  • Investors: Celgene, Deerfield and 13 Others
  • Latest Funding Round: Series D, Oct 25, 2022, $*****
  • Highlight: Editors' Pick

Tech Council Ventures' Investments by Stage

Tech Council Ventures has made 8 investments in Series A stage with an average round size of $9.57M, 5 investments in Seed stage with an average round size of $2.5M and 1 investment in Grant (prize money) stage with an average round size of $2.7M.
Here are Tech Council Ventures' investments by stage:
Stage of entry
No. of Investments
Series A
8
Seed
5
Grant (prize money)
1
Breakdown of Tech Council Ventures' investments by stage of entrySeries A (8)Seed (5)
Note: We have considered here, only first round of investments

Tech Council Ventures' Investments by Sector

Tech Council Ventures has a diverse portfolio, with companies operating in the Enterprise Applications, Chemicals and Materials, HealthTech, Life Sciences and Business Services. Notably, it has invested in 31 Enterprise (B2B) companies, 31 Tech companies, 15 Software companies and at least 10 companies focusing on Saas.
Here are Tech Council Ventures' investments by sector:
Sector
No. of Investments
Enterprise Applications
4
Chemicals and Materials
2
HealthTech
2
Life Sciences
2
Business Services
1
Others
12
Breakdown of Tech Council Ventures' investments by sectorsEnterprise Applic... (4)Chemicals and Mat... (2)
Note: We have considered here, only first round of investments

Tech Council Ventures' Investments by Geography

Tech Council Ventures has made most investments in United States (13), followed by Israel where it has made 1 investment.
Here are Tech Council Ventures' investments by geography:
Country
No. of Investments
United States
13
Israel
1
Breakdown of Tech Council Ventures' investments by countriesUnited States (13)Israel (1)
Note: We have considered here, only first round of investments

Tech Council Ventures' recent investments

Tech Council Ventures has made 2 investments in 2026 so far - Diameter Pay and PolyGone.
Here are the most recent investments by Tech Council Ventures:
Date
Company
Location
Round Details
Round Amount
Co-Investors
Sep 03, 2026
United States
Series A
8940
Feb 19, 2026
United States
Seed
1278
Oct 30, 2025
United States
Seed
5637
Feb 13, 2025
Israel
Grant (prize money)
6000
Feb 13, 2025
Israel
Seed
9051

IPOs and Publicly Listed companies in Tech Council Ventures' Portfolio

1 of Tech Council Ventures' portfolio company became public -  Cytosorbents. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jan 2013 at marketcap of undefined
Here are Tech Council Ventures' portfolio companies that went public:
Company
IPO Date
First Invested on
First Round of Investment
Round Size
Jan 07, 2013
-
-
8596

Acquired companies in Tech Council Ventures' Portfolio

18 companies from Tech Council Ventures' portfolio have been acquired. The most recent acquisition was Intra-Cellular Therapies in Jan 2025 by Johnson & Johnson for $*****.
Here are Tech Council Ventures' portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Jan 13, 2025
-
-
2571
Nov 08, 2023
-
-
8565
Mar 08, 2023
-
-
3585
Sep 01, 2022
Jan 08, 2019
Series A
1198
Aug 09, 2022
-
-
2211

Team profile of Tech Council Ventures

Tech Council Ventures has a team of 6 members including 4 Partners located in United States. Tech Council Ventures' team sits on the board of 1 company.
Here is a list of all team members in Tech Council Ventures:
Name
Designation
Location
Board Memberships
Contact Details
Partner
Summit
-
Partner
Trenton
-
Partner
Bridgewater
-
-
Partner
United States
-

Co-investors of Tech Council Ventures

Over the past 7 years, 81 investors have co-invested in Tech Council Ventures's portfolio companies. This includes funds and angels.

Recent News related to Tech Council Ventures

View all news related to Tech Council Ventures

FAQs about Tech Council Ventures

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford